Introduction
Disseminated candidiasis is a major manifestation of opportunistic invasive mycoses. Risk factors include prematurity, central venous catheters, prolonged use of antibiotics, immunodeficiencies, malignancies, malnutrition, steroid use, abnormal skin barriers, gastrointestinal tract defects and surgery. Septic arthritis occurs in 1-2 % of patients with disseminated candidiasis (Pérez-Gó mez et al., 1998) . Infants younger than 6 months of age comprise 85 % of paediatric cases with fungal arthritis. In children, the knee is the joint involved most often and Candida albicans is the fungus isolated in approximately 80 % of cases (Swanson et al., 1996) . Seventy to eighty per cent of septic arthritides caused by Candida occur in association with osteomyelitis (Lambertus et al., 1988; Swanson et al., 1996) .
Despite frequent colonization of the airways in cystic fibrosis (CF) patients by Candida and other fungi (Chotirmall et al., 2010) , invasive mycoses are rare and, to our knowledge, Candida osteoarticular infections have never been described so far in CF. Herein, we present a case of septic osteoarticular infection in a 12-month-old female patient with CF.
Case report
A 10-month-old female infant was admitted with severe failure to thrive, peripheral oedema, pneumonia and hypoproteinaemia (serum protein, 3.7 g dl 21 ; albumin, 1.9 g dl
21
; IgG, 282 mg dl
). She had a history of recurrent wheezing and multiple respiratory infections. The suspected diagnosis of CF was confirmed by three positive sweat tests and genetic testing (DF508 homozygote). Pneumonia was treated with intravenous cefotiam given via a peripheral indwelling catheter, whereon the patient showed clinical improvement (improved oral intake, slower and less shallow breathing). Selection of the antibiotic was based on a throat swab growing standard flora and non-Haemophilus influenzae species, but no other bacteria. However, after 9 days antibiotic therapy, the patient developed fever up to 40.6 uC, diarrhoea and elevated white blood cell count (WBC, 38 000 ml . Assessment of the joint by ultrasound revealed synovial thickening and an effusion of 5 mm. Magnetic resonance imaging (MRI) showed widespread myositis and osteomyelitis in the distal femoral epiphysis and patella, as well as gonarthritis (Fig. 1) . Arthrocentesis yielded purulent secretion (leukocytes, 3400 ml
; neutrophil granulocytes, 91 %) and evidence of C. albicans in culture and PCR (fully susceptible to amphotericin B, fluconazole and flucytosine). Cutaneous swabs and stool and blood cultures showed no evidence of C. albicans. Further evaluation yielded no additional fungal foci in the cranium, thorax or abdominal organs. Repeated evaluations for congenital immunodeficiency (oxidative burst, lymphocyte subpopulations, immunoglobulin levels including IgG subfractions, vaccination antibodies) were normal. ). In a follow-up MRI 10 days later, persisting myositis and gonarthritis were evident. The antifungal therapy was changed to fluconazole (12 mg kg 21 day
) and flucytosine (100 mg kg 21 day
). Clindamycin was stopped after 15 days (cultures were negative for bacteria). After slow clinical improvement over the initial 3 weeks of therapy, MRI showed progressive inflammation (Figs 1 and 2) ) and, since there was some discussion whether staphylococcal disease could be excluded fully, antibiotic therapy with clindamycin was restarted for 22 days. After 6 weeks, intravenous therapy was stopped and oral fluconazole was given for 4 additional months.
At follow-up examinations over 4 years, the girl was physically highly active with no sequelae and no signs of arthritis or movement restriction.
Discussion
Invasive bacterial or fungal diseases are rare in CF. To our knowledge, we describe the first patient with CF presenting with Candida osteoarticular infection. Six weeks prior to this infection, the patient had suffered candidaemia possibly facilitated by CF-related malnutrition, hypoproteinaemia with hypothesized secondary immunodeficiency, an indwelling peripheral intravenous catheter, and mucosal candidiasis during intravenous antibiotic therapy. Possibly, some transient immunodeficiency in our patient might also have facilitated the formation of a Candida nidus and the initial growth of the fungus in bradytrophic tissues. In our patient, there was no evidence for additional congenital immunodeficiency, which is a main risk factor for invasive candidiasis. There is also no evidence that patients with CF per se have a compromised defence against invasive Candida infections.
Guidelines for the treatment of candidaemia available at the time of disease in our patient recommended amphotericin B until complete resolution of signs and symptoms and at least for 14-21 days after the last positive blood culture (Pappas et al., 2004) . It is likely that the initial therapy with liposomal amphotericin B for 13 days was too short to be effective. As first-line therapy in Candida osteoarticular infections, an initial course of amphotericin B (3-5 mg kg 21 day
21
) for 2-3 weeks, followed by fluconazole (6 mg kg 21 twice daily) for a total duration of 6-12 months Fig. 1 . Sagittal MRI (T1 TSE) of the left knee over time. At baseline, increased contrast uptake of the synovia (asterisk) as well as the bursae (arrow) is seen; during follow-up after an initial increase in disease activity, significant reduction of pathological enhancement at the final control is observed. P, Patella; F, femur; T, tibia.
was recommended (Pappas et al., 2004) . The more recent guidelines of 2009 for the treatment of candidaemia and Candida osteoarticular infections allow starting therapy directly with fluconazole (6 mg kg 21 twice daily) in addition to the older guidelines (Pappas et al., 2004 (Pappas et al., , 2009 ).
In our case, amphotericin B was clinically not effective despite in vitro susceptibility of the isolated Candida cells. Therefore, we changed therapy to fluconazole and added flucytosine because low concentrations of fluconazole have been reported in bone by positron emission tomography (Fischman et al., 1993) and synergism has been described (Pérez-Gó mez et al., 1998; Rachapalli et al., 2010) . Due to the possible malabsorption of oral antifungal agents in patients with CF, we treated intravenously for 6 weeks. Our case indicates that the effect of the recommended antifungal drugs in bradytrophic tissue such as bones and joints might be reduced and that higher doses of drugs oras employed in our case -additional drugs might be required.
In addition to the antifungal drugs mentioned above, there is growing experience with echinocandins in children. Alternatively to the primary therapy regime, starting therapy with an echinocandin for several weeks followed by fluconazole for 6-12 months is also recommended in the guidelines (Pappas et al., 2009) . For caspofungin, attention should be paid to the importance of dosing based on body surface area rather than weight (50 mg m
22
). As the available recommendations (Pappas et al., 2004 (Pappas et al., , 2009 are based on limited data mostly from case reports or retrospective studies, further studies are needed.
Differential diagnosis of osteoarticular infections includes idiopathic rheumatoid arthritis and, in CF, CF-related arthropathy, which may also present with pain, swelling, tenderness and limitation of movement of joint as well as fever (Thornton & Rangaraj, 2009 ).
In conclusion, invasive Candida infections may occur in patients with CF and preventive measures should be considered in patients with risk factors such as malnutrition, prolonged antibiotic therapies and/or central venous catheters.
